LNTH INVESTOR ALERT: Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

Core Viewpoint - The Lantheus Holdings, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misrepresented its revenue outlook and growth potential during a specific class period [1][3]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products, particularly focusing on oncology, with its key product being Pylarify, a PET imaging agent for prostate cancer [2][3]. Allegations of the Lawsuit - The lawsuit claims that Lantheus executives created a false impression of the company's revenue outlook and growth while downplaying risks from competition and market dynamics [3]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to significant stock price declines following disappointing financial disclosures [3][4]. Financial Performance and Stock Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales and reduced its full-year growth projections, resulting in a stock price drop of over 23% [4]. - Following another disappointing announcement on August 6, 2025, which revealed an 8.3% year-over-year decline in Pylarify sales, the stock price fell nearly 29% [5]. Legal Process for Lead Plaintiff - Investors who purchased Lantheus securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6].